Inmune Bio Stock Filter Stocks by Fundamentals
| INMB Stock | USD 10.14 0.49 4.61% |
INmune Bio fundamentals help investors to digest information that contributes to INmune Bio's financial success or failures. It also enables traders to predict the movement of INmune Stock. The fundamental analysis module provides a way to measure INmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INmune Bio stock.
INmune | Shares Owned by Insiders |
INmune Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of INmune Bio from analyzing INmune Bio's financial statements. These drivers represent accounts that assess INmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of INmune Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 59.6M | 206.4M | 164.5M | 113.7M | 202.5M | 101.6M | |
| Enterprise Value | 52.8M | 184.6M | 105.0M | 76.8M | 177.1M | 185.9M |
INmune Bio Institutional Holders
Institutional Holdings refers to the ownership stake in INmune Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of INmune Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing INmune Bio's value.| Shares | Ubs Group Ag | 2023-12-31 | 43.2 K | Jane Street Group, Llc | 2023-12-31 | 43.1 K | Westside Investment Management, Inc. | 2023-12-31 | 41.9 K | Citigroup Inc | 2023-12-31 | 35.9 K | Bank Of New York Mellon Corp | 2023-12-31 | 33.4 K | Laird Norton Tyee Trust Co | 2023-12-31 | 31.5 K | Qube Research & Technologies | 2023-12-31 | 29.4 K | Fermata Advisors, Llc | 2023-12-31 | 29.4 K | Northern Trust Corp | 2023-12-31 | 25.1 K | Vanguard Group Inc | 2023-12-31 | 541.3 K | Blackrock Inc | 2023-12-31 | 257.9 K |
INmune Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (299.25) % | ||||
| Current Valuation | 158.18 M | ||||
| Shares Outstanding | 18.2 M | ||||
| Shares Owned By Insiders | 34.56 % | ||||
| Shares Owned By Institutions | 13.66 % | ||||
| Number Of Shares Shorted | 1.53 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 4.91 X | ||||
| Price To Sales | 1,208 X | ||||
| Revenue | 155 K | ||||
| Gross Profit | 374 K | ||||
| EBITDA | (29.74 M) | ||||
| Net Income | (30.01 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 10.44 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (11.98 M) | ||||
| Short Ratio | 22.49 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Target Price | 19.67 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.95 | ||||
| Market Capitalization | 184.58 M | ||||
| Total Asset | 57 M | ||||
| Retained Earnings | (121.02 M) | ||||
| Working Capital | 21.48 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
| Net Asset | 57 M |
About INmune Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.